Recombinant
RabMAb

Recombinant Anti-IGF2 antibody [EPR12221] (ab177467)

Submit a review Q&A (2)

Overview

  • Product name

    Anti-IGF2 antibody [EPR12221]
    See all IGF2 primary antibodies

  • Description

    Rabbit monoclonal [EPR12221] to IGF2

  • Host species

    Rabbit

  • Specificity

    ab177467 has been found not to cross react with mouse or rat IGF-2 in western blot testing.

  • Tested applications

    Suitable for: ICC/IF, WBmore details
    Unsuitable for: IHC-P or IP

  • Species reactivity

    Reacts with: Human
    Does not react with: Mouse, Rat

  • Immunogen

    Synthetic peptide within Human IGF2 aa 50-150 (internal sequence). The exact sequence is proprietary.
    Database link: P01344

  • Positive control

    • Recombinant human IGF2 protein (ab9575) can be used as a positive control in WB. Human serum lysate and HepG2 cells.

  • General notes

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

Applications

Our Abpromise guarantee covers the use of ab177467 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF 1/50 - 1/100.
WB 1/1000 - 1/5000. Predicted molecular weight: 20 kDa.
  • Application notes
    Is unsuitable for IHC-P or IP.

    • Target

    • Function

      The insulin-like growth factors possess growth-promoting activity. In vitro, they are potent mitogens for cultured cells. IGF-II is influenced by placental lactogen and may play a role in fetal development.
      Preptin undergoes glucose-mediated co-secretion with insulin, and acts as physiological amplifier of glucose-mediated insulin secretion. Exhibits osteogenic properties by increasing osteoblast mitogenic activity through phosphoactivation of MAPK1 and MAPK3.

    • Involvement in disease

      Epigenetic changes of DNA hypomethylation in IGF2 are a cause of Silver-Russell syndrome (SRS) [MIM:180860]. A clinically heterogeneous condition characterized by severe intrauterine growth retardation, poor postnatal growth, craniofacial features such as a triangular shaped face and a broad forehead, body asymmetry, and a variety of minor malformations. The phenotypic expression changes during childhood and adolescence, with the facial features and asymmetry usually becoming more subtle with age.

    • Sequence similarities

      Belongs to the insulin family.

    • Post-translational
      modifications

      O-glycosylated with core 1 or possibly core 8 glycans. Thr-96 is a minor glycosylation site compared to Thr-99.

    • Cellular localization

      Secreted.
    • Information by UniProt

    • Database links

      • Alternative names

        • C11orf43 antibody
        • FLJ22066 antibody
        • FLJ44734 antibody
        • GRDF antibody
        • IGF 2 antibody
        • IGF II antibody
        • IGF-II antibody
        • IGF2 antibody
        • IGF2_HUMAN antibody
        • IGFII antibody
        • INSIGF antibody
        • Insulin like growth factor 2 (somatomedin A) antibody
        • Insulin like Growth Factor 2 antibody
        • Insulin like growth factor II antibody
        • Insulin like growth factor II precursor antibody
        • Insulin like growth factor type 2 antibody
        • pp9974 antibody
        • Preptin antibody
        • Putative insulin like growth factor II associated protein antibody
        • Somatomedin A antibody
        • Somatomedin-A antibody
        • T3M 11 derived growth factor antibody
        see all

      Images

      • Immunocytochemistry/ Immunofluorescence - Anti-IGF2 antibody [EPR12221] (ab177467)
        Immunocytochemistry/ Immunofluorescence - Anti-IGF2 antibody [EPR12221] (ab177467)

        Immunofluorescence analysis of HepG2 cells labeling IGF2  (green)  with ab177467 at 1/50 dilution. DAPI nuclear staining (blue).

      • Western blot - Anti-IGF2 antibody [EPR12221] (ab177467)
        Western blot - Anti-IGF2 antibody [EPR12221] (ab177467)
        Anti-IGF2 antibody [EPR12221] (ab177467) at 1/1000 dilution + Human serum lysate at 10 µg

        Secondary
        Goat-anti-rabbit HRP at 1/2000 dilution

        Developed using the ECL technique.

        Predicted band size: 20 kDa

      References

      ab177467 has not yet been referenced specifically in any publications.

      Publishing research using ab177467? Please let us know so that we can cite the reference in this datasheet.

      Customer reviews and Q&As

      Show All Reviews Q&A
      Submit a review Submit a question

      1-2 of 2 Abreviews or Q&A

      Question

      x-reactivity with IGF1 determined?

      Read More
      Answer


      We haven't tested the cross-reactivity of ab177467 with IGF-1.
      However, based on the the immunogen sequence analysis the homology of the immunogen peptide is only 50% and no continuous sequences more than 3 aa could be found.
      It seems that there may be very little cross reactivity with IGF-1 (UniProt entry number P05019).

      Read More

      Question

      Obtaining a strong 50 kDa band and a faint 15 kDa band with ab177467. There seems to be a very faint band right below 50 kDa in the datasheet WB image, do you have any idea what this band is?

      Read More
      Answer

      The laboratory completed the blocking study for ab177467 (IGF2), and found that the blocking peptide did successfully block the 50 kDa band, indicating that this band is associated with the immunogen.

      We found the 2 attached papers, which cite that a 50 kDa complex does exist for both IGF1 and IGF2 in serum, so these complexes may be present in your mouse skin as well.

      From IGF1 paper:

      “In serum, the majority (70–80%) of the IGFs exist in a 150-kDa complex comprised of one IGF molecule, IGFBP-3, and the acid labile subunit (ALS). A smaller proportion (∼20%) of the IGFs are associated with other serum IGFBPs within a 50-kDa complex, and less than 5% of the IGFs are found in the free form of 7.5 kDa.”

      From IGF2 paper:

      ˜50kDa complex formed by IGF-II and IGFBP in the circulation.

      Read More

      Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
      For licensing inquiries, please contact partnerships@abcam.com